Eupraxia Pharmaceuticals' (EPRX) once-yearly EP-104GI injection could serve a distinct group of patients with eosinophilic esophagitis, RBC Capital Markets said in a Monday note.
The investigational treatment combines a US Food and Drug Administration approved corticosteroid with the company's DiffuSphere delivery platform designed to maintain drug levels in the esophagus for nine to 12 months following a single endoscopic administration, according to the note.
Early-stage phase 1b and 2a data showed about 80% symptomatic remission and a clean safety profile, RBC said. A phase 2b interim data readout is expected in the first two weeks of December, the firm said.
RBC initiated coverage of Eupraxia Pharmaceuticals with an outperform, speculative risk rating and $14 price target.
Eupraxia Pharmaceuticals shares were 8.7% higher in Monday trading.
Price: 7.49, Change: +0.60, Percent Change: +8.71
Comments